Rigel Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.08.22	Rigel Pharmaceuticals Inc. Q2 Loss beats estimates (RTTNews)
02.08.22	Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
02.08.22	Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
08.06.22	Why Rigel Pharma Stock Falling In Pre-market? (RTTNews)
08.06.22	Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia (PR Newswire)
04.05.22	ATRC Sees 16-20% Revenue Growth, RIGL On Watch, LUNG Breathes Easy, BPMC Braces For Busy Year (RTTNews)
03.05.22	Rigel Pharmaceuticals Inc. Q1 Earnings Summary (RTTNews)
03.05.22	Rigel Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
08.03.22	Rigel : Phase 2 Study Of Fostamatinib Shows Clinically Meaningful Hemoglobin Responses (RTTNews)
08.03.22	Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology (PR Newswire)
01.03.22	Rigel Pharmaceuticals Inc. Q4 loss increases in line with estimates (RTTNews)
01.03.22	Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (PR Newswire)
10.01.22	Rigel Pharmaceuticals Provides Business Update (PR Newswire)
21.12.21	Rigel Pharma Says Fostamatinib Met Primary Endpoint In Phase 3 Trial In Japan - Quick Facts (RTTNews)
21.12.21	Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia (PR Newswire)
16.12.21	Rigel Appoints Kamil Ali-Jackson to Board of Directors (PR Newswire)
22.11.21	Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
15.11.21	Rigel Pharma To Exit Early-stage Research; To Cut Workforce - Quick Facts (RTTNews)
15.11.21	Rigel Sharpens Focus on Its Advanced Portfolio Opportunities (PR Newswire)
02.11.21	Rigel Pharmaceuticals Inc. Q3 Earnings Summary (RTTNews)
02.11.21	Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
01.09.21	Rigel's Phase 2 Data Of Fostamatinib In COVID-19 Patients Published In Clinical Infectious Diseases (RTTNews)
01.09.21	Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases (PR Newswire)
16.08.21	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL (PR Newswire)
13.08.21	Rigel : FDA Didn't Issue EUA For Fostamatinib For Treatment Of COVID-19 In Hospitalized Adults (RTTNews)
13.08.21	Rigel Pharmaceuticals Provides Update on COVID-19 Program (PR Newswire)
03.08.21	EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q2 Earnings Report (RTTNews)
03.08.21	Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
27.07.21	Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update (PR Newswire)
14.07.21	New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress (PR Newswire)
29.06.21	Rigel's Fostamatinib Selected For NIH ACTIV-4 COVID-19 Clinical Trial (RTTNews)
29.06.21	Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial (PR Newswire)
05.05.21	Rigel Pharmaceuticals Inc. Bottom Line Rises In Q1 (RTTNews)
13.04.21	Rigel Pharma Says Phase 2 Trial Of Fostamatinib For COVID-19 Met Primary Endpoint Of Safety (RTTNews)
11.03.21	Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients (RTTNews)
02.03.21	EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q4 Earnings Report (RTTNews)
19.02.21	FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLY (RTTNews)
18.02.21	Lilly, Rigel To Develop RIPK1 Inhibitors For Treatment Of Immunological & Neurodegenerative Diseases (RTTNews)
11.01.21	Rigel Pharma Says TAVALISSE Preliminary 2020 Net Product Sales Up 41% - Quick Facts (RTTNews)
17.11.20	Rigel Reaches Agreement With FDA On Study Design Of Phase 3 Trial Of Fostamatinib (RTTNews)
05.11.20	EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q3 Earnings Report (RTTNews)
09.10.20	Rigel Pharma : First Patient Enrolled In Fostamatinib Trial In Hospitalized COVID-19 Patients (RTTNews)
17.09.20	Rigel Pharma Begins Phase 2 Trial Of Fostamatinib In Hospitalized COVID-19 Patients (RTTNews)
04.08.20	EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q2 Earnings Report (RTTNews)
16.07.20	GRTX Awaits Pancreatic Cancer Trial Data, GENE Jumps, MNK Gets FDA Panel Backing, TCDA Disappointed (RTTNews)
15.07.20	Pre-market Movers In Healthcare Sector: IMMP, ACOR, CLSN, MRNA, ECOR... (RTTNews)
15.07.20	AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On Watch (RTTNews)
14.07.20	Stock Alert: Rigel Pharma Soars 80% (RTTNews)
14.07.20	Rigel Announces Investigator-Sponsored Trial Of Fostamatinib In Patients With COVID-19 Pneumonia (RTTNews)
05.05.20	EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q1 Earnings Report (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V

Nachrichten zu Rigel Pharmaceuticals IncShs

Aktien Top/Flop

Meistgelesene Nachrichten